Kimo C. Stine

High Impact

Researcher

UAMS

Faculty Researcher

27 h-index 83 pubs 2,469 cited

Research Areas

Biomedical Subjects

Links

ORCID

OverviewAI-generated summary

Kimo C. Stine's research focuses on investigating the mechanisms and potential treatments for various medical conditions, with a particular emphasis on cardiotoxicity and genetic disorders. His work includes studies on doxorubicin-induced cardiotoxicity, exploring biomarkers for early detection and understanding its chronic effects. Stine has also been involved in research concerning gene therapy for hemophilia A, analyzing the outcomes and safety of novel treatments.

Further contributing to the understanding of rare genetic conditions, Stine has worked on resolving variants of uncertain significance in genes associated with syndromes like Li-Fraumeni. His publications demonstrate a commitment to exploring predictive risk factors for myocardial injury in pediatric patients undergoing chemotherapy, aiming to improve treatment strategies and patient outcomes. Stine's scholarship metrics, including an h-index of 27 and over 2,400 citations, reflect his significant contributions to the field. He has collaborated with researchers from the National Center for Toxicological Research on multiple projects.

Metrics

h-index: 27
Publications: 83
Citations: 2,469

Selected Publications

Correction: Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study (2026)

Cardiovascular Toxicology DOI OpenAlex
Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study (2025)

Cardiovascular Toxicology DOI OpenAlex
A Novel Germline TP53 Mutation in a Patient With Li-Fraumeni Syndrome: Resolving a Variant of Uncertain Significance (2021)

Journal of Pediatric Hematology/Oncology 1 citation DOI OpenAlex
A NOVEL GERMLINE TP53 MUTATION IN A PATIENT WITH LI-FRAUMENI SYNDROME - RESOLVING A VARIANT OF UNCERTAIN SIGNIFICANCE (2020)

DOI OpenAlex
Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study (2016)

Pediatric Blood & Cancer 93 citations DOI OpenAlex
Nutlin‐3 treatment spares cisplatin‐induced inhibition of bone healing while maintaining osteosarcoma toxicity (2016)

Journal of Orthopaedic Research® 8 citations DOI OpenAlex
The genomic landscape of juvenile myelomonocytic leukemia (2015)

Nature Genetics 310 citations DOI OpenAlex
von Willebrand Factor Multimers in Pediatric Extracorporeal Membrane Oxygenation Support (2014)

ASAIO Journal 27 citations DOI OpenAlex
Case studies in the management of refractory bleeding in patients with haemophilia A and inhibitors (2013)

Haemophilia 6 citations DOI OpenAlex
Cisplatin inhibits bone healing during distraction osteogenesis (2013)

Journal of Orthopaedic Research® 40 citations DOI OpenAlex
C-Reactive Protein and Soluble IL-2Receptor Correlate with High Risk of Clinical Sepsis Among Children with Fever and Neutropenia. (2009)

Blood DOI OpenAlex
Surgical interventions in a cohort of patients with haemophilia A and inhibitors: an experiential retrospective chart review (2007)

Haemophilia 33 citations DOI OpenAlex
Use of FEIBA for Invasive or Surgical Procedures in Patients With Severe Hemophilia A or B With Inhibitors (2007)

Journal of Pediatric Hematology/Oncology 19 citations DOI OpenAlex
Treatment of Deep Vein Thrombosis With Enoxaparin in Pediatric Cancer Patients Receiving Chemotherapy (2007)

Clinical and Applied Thrombosis/Hemostasis 15 citations DOI OpenAlex
A patient with hyperuricemia and renal failure:answer (2007)

Pediatric Nephrology 1 citation DOI OpenAlex